Amplia uncovers new clue in pancreatic cancer drug trial
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.
More news
- Rwanda: 'Be Healthy First' - Kagame Tells Youth
- Дети попали в больницу, после того как поели фастфуд в Астане
- Africa: Africa Becoming an Increasingly Central Hub for Latin American Drug Cartels
- From Robin’s Hall to Florida healthcare pioneer
- WHO warns Pacific Health systems face growing climate and funding pressures